BHC 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
BHC 近期報酬表現
1.87%
Bausch health companies inc
1.19%
同產業平均
1.11%
S&P500
與 BHC 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
VIRX | Viracta therapeutics inc | 3 分 | 1 分 | 2 分 | 1 分 | 1 分 | |
SVRA | Savara inc | 2 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
ENVB | Enveric biosciences inc | 3 分 | 2 分 | 3 分 | 1 分 | 1 分 | |
CLRB | Cellectar biosciences inc | 2 分 | 2 分 | 2 分 | 2 分 | 1 分 | |
IMCC | Im cannabis corp | 2 分 | 2 分 | 2 分 | - | 1 分 |
- VIRX Viracta therapeutics inc價值 3 分趨勢 1 分波段 2 分籌碼 1 分股利 1 分查看更多
BHC 公司資訊
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.